Launch One Acquisition Corp.
LPAAW
NASDAQ Global Market0.18
USD
+0.02
- -
CIK
0002015502
ISIN
KYG5S86M1260
Return %
Stock
S&P500
1Y
-33.33
26.84
3Y
100.00
77.03
5Y
100.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher Ehrlich
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 180 Grand Avenue Oakland CA Cayman Islands 94612
- IPO Date
- Jul 11, 2024
- CIK
- 0002015502
- Website
- launchoneacquisitioncorp.com
- Similar Companies
- Business
- Launch One Acquisition Corp. is a blank check company whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar initial business combination with one or more businesses, with a targeted focus on the life sciences sector; it currently conducts no significant operations. Incorporated on February 21, 2024, as a Cayman Islands exempted company and headquartered at 180 Grand Avenue, Suite 1530, Oakland, California, the company offers investors units comprising Class A ordinary shares and warrants, which began separate trading on Nasdaq under the symbols LPAA, LPAAU, and LPAAW following its initial public offering priced at $200 million on July 11, 2024. In a major recent development, Launch One Acquisition Corp. signed a definitive business combination agreement on June 25, 2025, with Minovia Therapeutics Ltd., an Israel-based biotechnology firm developing mitochondrial augmentation therapy (MAT) for rare diseases and oncology indications, pursuant to which Minovia will merge with a wholly owned subsidiary of Launch One Acquisition, with Launch One Acquisition surviving the merger as a publicly listed entity on Nasdaq at a pre-money enterprise valuation of approximately $180 million for Minovia. The transaction, which remains subject to customary closing conditions including shareholder approval, represents the company's primary strategic initiative to date, with an initial business combination deadline of up to 24 months from its IPO closing or earlier board-approved liquidation. Led by Chairman Ryan Gilbert, Chief Executive Officer Christopher B. Ehrlich, and Chief Financial Officer Jurgen van de Vyver—all with prior experience in SPAC transactions including the 2021 Locust Walk/eFFECTOR Therapeutics merger—the firm targets opportunities accessible through its management team's networks in biotechnology and life sciences across the United States and internationally.